Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Medicure.

    Client Virtual Booth

    MEDICURE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Medicure
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    2-1250 Waverley Street Winnipeg, Manitoba R3T 6C6
    Telephone
    Telephone
    204-487-7412
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.medicure.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/medicure/
    Twitter
    Twitter
    https://twitter.com/MedicureInc

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

    Details:

    FDA provides complete approval to enroll patients in its pivotal clinical trial to evaluate "MC-1" (a naturally occurring metabolite of pyridoxine) for treatment of a rare pediatric disease called pyridox(am)ine 5′-phosphate oxidase deficiency.


    Lead Product(s): Pyridoxal Phosphate

    Therapeutic Area: Rare Diseases and Disorders Product Name: MC-1

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 23, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medicure Announces an Agreement with Reliance Life Sciences for the Marketing Rights of a Cardiovascular Biosimilar

    Details:

    The Agreement grants an exclusive right to Medicure to market and sell the Product in the United States of America, Canada and the European Union.


    Lead Product(s): Undisclosed

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Recipient: Reliance Life Sciences Private Limited

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement October 05, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

    Details:

    Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.


    Lead Product(s): Tirofiban,Clopidogrel,Aspirin

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT

    Details:

    The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.


    Lead Product(s): Tirofiban,Prasugrel

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat

    Highest Development Status: Phase IVProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search